Publications by authors named "J G Petros"
Hepatocellular carcinoma (HCC) progression is facilitated by gene-silencing chromatin histone hypoacetylation due to histone deacetylase (HDAC) activation. However, inhibiting HDACs-an effective treatment for lymphomas-has shown limited success in solid tumors. We report the discovery of a class of HDAC inhibitors (HDACi) that demonstrates exquisite selective cytotoxicity against human HCC cells.
View Article and Find Full Text PDFHepatocellular cancer (HCC) progression is facilitated by gene-silencing chromatin histone hypoacetylation due to histone deacetylases (HDACs) activation. However, inhibiting HDACs, an effective treatment for lymphomas, has shown limited success in solid tumors. We report the discovery of a class of HDAC inhibitors (HDACi) that demonstrates exquisite selective cytotoxicity against human HCC cells.
View Article and Find Full Text PDFBackground: Chronic pain has long been a major health burden that has been addressed through numerous forms of pharmacological and nonpharmacological treatment. One of the tenets of modern medicine is to minimize risk while providing efficacy. Further, because of its noninvasive nature, virtual reality (VR) provides an attractive platform for potentially developing novel therapeutic modalities.
View Article and Find Full Text PDFArticle Synopsis
- Mutations in the SETD2 gene are common in renal cell carcinoma (RCC), and a specific single nucleotide polymorphism (SNP), E902Q, was found in some RCC patients as an inherited or tumor-related mutation.
- Researchers used CRISPR to create a similar mutation in the fruit fly gene Set2, discovering that it significantly lowered an important histone modification (H3K36me3) and led to problems with spindle formation during cell division.
- The findings suggest that the SETD2 E902Q SNP not only influences histone methylation and spindle integrity but could also have important implications for understanding and treating RCC clinically.
Background Context: A previous cost-effectiveness analysis published in 2022 found that the Total Posterior Spine (TOPS) system was dominant over transforaminal lumbar interbody fusion (TLIF). This analysis required updating to reflect a more complete dataset and pricing considerations.
Purpose: To evaluate the cost-effectiveness of TOPS system as compared with TLIF based on an updated and complete FDA investigational device exemption (IDE) data set.